Sanofi (NASDAQ:SNY) Cut to Hold at Wall Street Zen

Wall Street Zen downgraded shares of Sanofi (NASDAQ:SNY) from a buy rating to a hold rating in a research report released on Saturday morning.

Several other analysts have also commented on the stock. Morgan Stanley set a $49.00 target price on shares of Sanofi in a research note on Wednesday, July 8th. BNP Paribas Exane lowered shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target on the stock. in a research report on Monday, April 20th. Weiss Ratings raised Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Argus upgraded Sanofi to a “strong-buy” rating in a research report on Monday, April 27th. Finally, Citigroup reissued a “neutral” rating on shares of Sanofi in a research note on Monday, April 13th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $49.50.

Sanofi Price Performance

NASDAQ:SNY opened at $43.98 on Friday. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17. The business’s 50-day moving average price is $43.38 and its 200 day moving average price is $45.47. Sanofi has a 52-week low of $40.89 and a 52-week high of $52.68. The firm has a market cap of $106.63 billion, a P/E ratio of 12.28, a PEG ratio of 1.14 and a beta of 0.34.

Institutional Investors Weigh In On Sanofi

A number of institutional investors have recently bought and sold shares of the business. Brighton Jones LLC boosted its holdings in shares of Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock worth $261,000 after purchasing an additional 1,869 shares during the period. AQR Capital Management LLC lifted its position in Sanofi by 107.2% in the 1st quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock worth $1,693,000 after buying an additional 15,791 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Sanofi by 1.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock worth $2,732,000 after buying an additional 752 shares in the last quarter. Sivia Capital Partners LLC boosted its stake in shares of Sanofi by 5.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock valued at $326,000 after buying an additional 347 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its stake in shares of Sanofi by 36.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,301 shares of the company’s stock valued at $159,000 after buying an additional 875 shares during the period. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.